Press release
Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available
Available for purchase today at Stelo.com for people in the U.S. 18 and older not using insulin Provides 24/7 powerful and personalized glucose insights
About this update from Dexcom, Inc.
[{"type":"text","content":"\n\nAvailable for purchase today at Stelo.com for people in the U.S. 18 and older not using insulin\n\n\n\nProvides 24/7 powerful and personalized glucose insights directly to a smartphone,* revealing how food, exercise and sleep can affect glucose\n\n\n\nTracking glucose just got easier, with no prescription and no fingersticks, ever\n\n\n\nSpecifically designed to help people with Type 2 diabetes not using insulin and those with prediabetes reach their A1c goals and potentially slow the progression of diabetes.†,1-3\n\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nDexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter glucose biosensor in the U.S., is now available for purchase without a prescription4 at Stelo.com.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240826019839/en/Stelo is designed to help people with Type 2 diabetes not using insulin and those with prediabetes. (Photo: Dexcom)\nStelo is a small biosensor worn on the back of the upper arm that leverages Dexcom’s most accurate glucose sensing technology.5 It is specifically designed to provide the 125 million Americans6 with Type 2 diabetes not using insulin and those with prediabetes with powerful, personalized glucose insights sent directly to a smartphone,* revealing how food, exercise and sleep can affect glucose – all without painful fingersticks.\n\n\n“Dexcom has been at the forefront of glucose biosensing for 25 years. With the launch of Stelo, we’re defining a brand-new category and once again setting the gold standard for people to easily take control of their health,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Now, millions more have access to 24/7, easy-to-understand glucose insights that can inform their daily lifestyle choices and support behavior modification.”\n\n\nThe benefits of glucose biosensing have been shown when used alone, or alongside other diabetes and weight management medications.7 Studies show the use of Dexcom glucose biosensing by people with Type 2 diabetes is associated with clinically meaningful improvement in time in range, A1c and quality of life.8-11\n\n\n“Dexcom glucose biosensors are an essential and proven tool for diabet...